EGFR and neoplasm: Our analysis showed a significant longer PFS and OS for patients treated with anti-EGFR vs R/T in the L-sided tumor group [median PFS 7.2 vs 3.6 months, HR 0.43 (95% CI 0.2-0.76), p=0.004; median OS 14.9 vs 10.9 months, HR 0.52 (95% CI 0.28-0.98), p=0.045].